CRON Valuation

Cronos Group Inc

Add to Watchlist

Advanced Chart

2.600

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

CRON Relative Valuation

CRON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRON is overvalued; if below, it's undervalued.

Historical Valuation

Cronos Group Inc (CRON) is now in the Fair zone, suggesting that its current forward PS ratio of 5.60 is considered Fairly compared with the five-year average of 369.84. The fair price of Cronos Group Inc (CRON) is between 1.20 to 10.73 according to relative valuation methord.

Relative Value

Fair Zone

1.20-10.73

Current Price：2.60

Fair

128.03

Trailing

Forward

7.75

EV/EBITDA

Cronos Group Inc. (CRON) has a current EV/EBITDA of 7.75. The 5-year average EV/EBITDA is -2.92. The thresholds are as follows: Strongly Undervalued below -24.26, Undervalued between -24.26 and -13.59, Fairly Valued between 7.75 and -13.59, Overvalued between 7.75 and 18.41, and Strongly Overvalued above 18.41. The current Forward EV/EBITDA of 7.75 falls within the Overvalued range.

-129.79

EV/EBIT

Cronos Group Inc. (CRON) has a current EV/EBIT of -129.79. The 5-year average EV/EBIT is -3.62. The thresholds are as follows: Strongly Undervalued below -32.71, Undervalued between -32.71 and -18.17, Fairly Valued between 10.92 and -18.17, Overvalued between 10.92 and 25.47, and Strongly Overvalued above 25.47. The current Forward EV/EBIT of -129.79 falls within the Strongly Undervalued range.

5.60

Cronos Group Inc. (CRON) has a current PS of 5.60. The 5-year average PS is 14.59. The thresholds are as follows: Strongly Undervalued below -11.06, Undervalued between -11.06 and 1.76, Fairly Valued between 27.42 and 1.76, Overvalued between 27.42 and 40.25, and Strongly Overvalued above 40.25. The current Forward PS of 5.60 falls within the Historic Trend Line -Fairly Valued range.

31.79

P/OCF

Cronos Group Inc. (CRON) has a current P/OCF of 31.79. The 5-year average P/OCF is 32.56. The thresholds are as follows: Strongly Undervalued below -439.05, Undervalued between -439.05 and -203.24, Fairly Valued between 268.36 and -203.24, Overvalued between 268.36 and 504.17, and Strongly Overvalued above 504.17. The current Forward P/OCF of 31.79 falls within the Historic Trend Line -Fairly Valued range.

66127.13

P/FCF

Cronos Group Inc. (CRON) has a current P/FCF of 66127.13. The 5-year average P/FCF is 1740.35. The thresholds are as follows: Strongly Undervalued below -17539.91, Undervalued between -17539.91 and -7899.78, Fairly Valued between 11380.49 and -7899.78, Overvalued between 11380.49 and 21020.62, and Strongly Overvalued above 21020.62. The current Forward P/FCF of 66127.13 falls within the Strongly Overvalued range.

Cronos Group Inc (CRON) has a current Price-to-Book (P/B) ratio of 0.92. Compared to its 3-year average P/B ratio of 0.75 , the current P/B ratio is approximately 22.57% higher. Relative to its 5-year average P/B ratio of 1.03, the current P/B ratio is about -10.44% higher. Cronos Group Inc (CRON) has a Forward Free Cash Flow (FCF) yield of approximately -0.92%. Compared to its 3-year average FCF yield of -5.51%, the current FCF yield is approximately -83.35% lower. Relative to its 5-year average FCF yield of -6.83% , the current FCF yield is about -86.56% lower.

0.92

P/B

Median3y

0.75

Median5y

1.03

-0.92

FCF Yield

Median3y

-5.51

Median5y

-6.83

Competitors Valuation Multiple

The average P/S ratio for CRON's competitors is 5.06, providing a benchmark for relative valuation. Cronos Group Inc Corp (CRON) exhibits a P/S ratio of 5.65, which is 11.60% above the industry average. Given its robust revenue growth of 20.51%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Cidara Therapeutics Inc

Niagen Bioscience Inc

USANA Health Sciences Inc

Nature's Sunshine Products Inc

0.63

3.80%

297.16M

Performance Decomposition

Market capitalization of CRON increased by 15.04% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -31.55 to -115.03.

The secondary factor is the Revenue Growth, contributed 20.51%to the performance.

Overall, the performance of CRON in the past 1 year is driven by Margin Expansion. Which is more sustainable.

20.51%

27.76M → 33.46M

Revenue Growth

264.60%

-31.55 → -115.03

Margin Expansion

-270.07%

-31.69 → 53.89

P/E Change

15.04%